

*a2* 7. (Amended) A recombinant vector comprising the gene according to claim 3.

*a3* 10. (Amended) An antibody against the protein according to claim 1.

11. (Amended) A pharmaceutical composition for regulating neuronal functions, comprising the protein according to claim 1.

12. (Amended) A therapeutic agent for neurological diseases comprising the protein according to claim 1 as an active ingredient.

13. (Amended) A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 3.

14. (Amended) A therapeutic agent for neurological diseases, comprising the gene according to claim 3.

*a4* 16. (Amended) A reagent for detecting Synaptotagmin, comprising the protein according to claim 1.

*a5* 19. (Amended) A method of detecting Synaptotagmin, comprising:

- (a) fractionating a sample;
- (b) reacting the resultant fractions with the protein wherein an isolated protein comprising an amino acid sequence selected from SEQ. ID NO: 2 which has been labeled;
- (c) reacting the reaction products obtained in step (b) above with the antibody according to claim 10 which has been labeled; and
- (d) detecting a signal from the reaction products obtained in step (c) above.

**Please add the following new claims:**

21. (New) A recombinant vector comprising the gene according to claim 4.
22. (New) A recombinant vector comprising the gene according to claim 5.
23. (New) A recombinant vector comprising the gene according to claim 6.
24. (New) An antibody against the protein according to claim 2.
25. (New) A pharmaceutical composition for regulating neuronal functions, comprising the protein according to claim 2.
26. (New) A therapeutic agent for neurological diseases comprising the protein according to claim 2 as an active ingredient.
27. (New) A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 4.
28. (New) A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 5.
29. (New) A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 6.
30. (New) A therapeutic agent for neurological diseases, comprising the gene according to claim 4.
31. (New) A therapeutic agent for neurological diseases, comprising the gene according to claim 5.

32. (New) A therapeutic agent for neurological diseases, comprising the gene according to claim 6.
33. (New) A reagent for detecting Synaptotagmin, comprising the protein according to claim 2.
34. (New) A reagent for detecting Synaptotagmin, comprising the protein according to claim 10.
35. (New) A reagent for detecting Synaptotagmin, comprising the antibody according to claim 10.
36. (New) A method of detecting Synaptotagmin, comprising:
- (a) fractionating a sample;
  - (b) reacting the resultant fractions with a protein comprising an amino acid sequence, which has been labeled, selected from the group consisting of SEQ. ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 4 that has deletion, substitution or addition of one to ten amino acids within the region from position 1 to position 400 and that has RNA binding activity;
  - (c) reacting the reaction products obtained in step (b) with the antibody according to claim 10 which has been labeled; and
  - (d) detecting a signal from the reaction products obtained in step (c) above.